Valneva SE
VALN
查看详细走势图
8.485USD
+0.125+1.50%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.38B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.50%
5天
+2.97%
1月
-3.80%
6月
+51.52%
今年开始到现在
+94.08%
1年
+102.51%
查看详细走势图
TradingKey Valneva SE股票评分
单位: USD 更新时间: 2025-12-24操作建议
Valneva SE当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名114/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.89。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Valneva SE评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
12.887
目标均价
+44.48%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Valneva SE亮点
亮点风险
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
估值高估
公司最新PE估值-7.66，处于3年历史高位
机构加仓
最新机构持股4.53M股，环比增加44.31%
活跃度增加
近期活跃度增加，过去20天平均换手率3.26
Valneva SE新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Valneva SE简介
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
公司代码VALN
公司Valneva SE
CEOLingelbach (Thomas)
网址https://valneva.com/
常见问题
Valneva SE(VALN)的当前股价是多少？
Valneva SE(VALN)的当前股价是 8.485。
Valneva SE的股票代码是什么？
Valneva SE的股票代码是VALN。
Valneva SE股票的52周最高点是多少？
Valneva SE股票的52周最高点是12.250。
Valneva SE股票的52周最低点是多少？
Valneva SE股票的52周最低点是4.021。
Valneva SE的市值是多少？
Valneva SE的市值是1.38B。
Valneva SE的净利润是多少？
Valneva SE的净利润为-12.25M。
现在Valneva SE(VALN)的股票是买入、持有还是卖出？
根据分析师评级，Valneva SE(VALN)的总体评级为买入，目标价格为12.887。
Valneva SE(VALN)股票的每股收益（EPS TTM）是多少
Valneva SE(VALN)股票的每股收益（EPS TTM）是-1.108。
相关品种
